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Background: The purpose of this study was to compare, from a Chinese societal perspective, the projected health
benefits, costs, and cost-effectiveness of adding pneumococcal conjugate heptavalent vaccine (PCV-7) to the
routine compulsory child immunization schedule.
Methods: A decision-tree model, with data and assumptions adapted for relevance to China, was developed to
project the health outcomes of PCV-7 vaccination (compared with no vaccination) over a 5-year period as well as a
lifetime. The vaccinated birth cohort included 16,000,000 children in China. A 2 + 1 dose schedule at US$136.51 per
vaccine dose was used in the base-case analysis. One-way sensitivity analysis was used to test the robustness of the
model. The impact of a net indirect effect (herd immunity) was evaluated. Outcomes are presented in terms of the
saved disease burden, costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio.
Results: In a Chinese birth cohort, a PCV-7 vaccination program would reduce the number of pneumococcus-
related infections by at least 32% and would prevent 2,682 deaths in the first 5 years of life, saving $1,190 million
in total costs and gaining an additional 9,895 QALYs (discounted by 3%). The incremental cost per QALY was
estimated to be $530,354. When herd immunity was taken into account, the cost per QALY was estimated to be
$95,319. The robustness of the model was influenced mainly by the PCV-7 cost per dose, effectiveness herd
immunity and incidence of pneumococcal diseases. With and without herd immunity, the break-even costs in China
were $29.05 and $25.87, respectively.
Conclusions: Compulsory routine infant vaccination with PCV-7 is projected to substantially reduce pneumococcal
disease morbidity, mortality, and related costs in China. However, a universal vaccination program with PCV-7 is not
cost-effective at the willingness-to-pay threshold that is currently recommended for China by the World Health
Organization.
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Streptococcus pneumoniae (S. pneumoniae) is the single
most significant bacterial cause of invasive (meningitis
and bacteremia) and noninvasive (pneumonia and otitis
media) diseases in children <5 years of age worldwide [1].
In China, pneumococcal diseases pose a major burden in
young children and the elderly, leading to nearly 30,000
deaths annually [2-4]. Pneumococcal diseases caused by S.* Correspondence: wbwithtg@hotmail.com
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reproduction in any medium, provided the orpneumoniae are primarily treated with penicillin; however,
the increasing prevalence of drug-resistant pneumococci
is a concern worldwide and demands more sophisticated
disease management. The treatment of infections caused
by antibiotic-resistant S. pneumoniae would require more
resources, including more expensive antibiotic agents and
longer hospital stays, which would substantially increase
healthcare expenditures [5-7].
New pneumococcal conjugate vaccines have been de-
veloped to protect infants and young children from
pneumococcal diseases [8,9]. The heptavalent pneumococ-
cal conjugate vaccine (PCV-7) Prevnar® (Pfizer Vaccines). This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Drug Administration, and it has been available since 2000.
PCV-7 is composed of seven saccharides from the capsular
antigen of S. pneumoniae, each conjugated to a CRM197
protein, which is a nontoxic mutant of diphtheria toxin
carrier. PCV-7 contains the serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F, which cause the majority of cases of invasive
pneumococcal disease (IPD) worldwide [10-12]. The clin-
ical effectiveness and safety of PCV-7 in infants and chil-
dren have been evaluated in several large-scale clinical
trials. The results demonstrate that vaccination signifi-
cantly decreased the incidence rates of IPD, pneumonia,
and otitis media [13-15]. Furthermore, surveillance data in-
dicated that PCV-7 could reduce the incidence rate of
pneumococcal disease in both vaccinated infants and in
unvaccinated infants by “herd immunity”. The direct effect
of the vaccine could also extend the benefit to adults by de-
creasing the nasopharyngeal presence of S. pneumoniae in
vaccinated children [16-18]. At present, new vaccines of
higher valence, namely, a 10-valent vaccine (PCV-10)
called Synflorix® (GlaxoSmithKline) and a 13-valent vaccine
(PCV-13) (Pfizer Vaccines), have been approved to replace
PCV-7 in the future.
Following recommendations from the Strategic Advisory
Group of Experts on Immunization, the World Health
Organization (WHO) suggests that the pneumococcal con-
jugate vaccine should be included in national immunization
programs to reduce the heavy pneumococcal disease bur-
den [19]. Over the last decade, many developed countries
have added a pneumococcal vaccine to compulsory, routine
immunization schedules [20]. In poor countries, multilat-
eral organizations, including the Global Alliance for Vac-
cines and Immunization (GAVI), have taken an active role
in improving access to vaccines [21]. At present, PCV-7 is
the only pneumococcal conjugate vaccine licensed for use
in infants and young children in China; however, the intro-
duction of PCV-7 into the Chinese national immunization
program still poses a challenge due to the high cost of the
imported vaccine. The economic outcome of public health
interventions is an important factor in policy decisions. Al-
though economic outcomes in developed countries indicate
that a universal PCV-7 vaccination program could reduce
both medical and nonmedical costs, there is little economic
evidence to support the universal use of this vaccine in
China [22]. The aim of the present study was to evaluate
the projected health benefits, costs, and cost-effectiveness
of universal infant vaccination with PCV-7 in China.
Methods
Analytical and model overview
We used a decision tree-based mathematical model to
estimate the costs and epidemiological impact of various
vaccination scenarios [23]. The generic statistical model
was programmed in R (version 2.14.1; R DevelopmentCore Team, Vienna, Austria) to project pneumococcal dis-
ease outcomes from birth to death for a hypothetical
Chinese birth cohort of 16 million infants. A 5-year period
was used because the effectiveness of this vaccine has yet
to be determined. We assumed that each newborn entered
the model healthy but at risk of incurring pneumococcal
disease and developing adverse health outcomes. To esti-
mate the long-term impact of pneumococcal disease, we
extrapolated the lifetime outcomes of the individuals in
the cohort (that is, until death at a maximum of 100 years
of age). When indirect effects (herd immunity) are in-
cluded in the model, adults in the family are considered to
be at risk for developing IPD.
We estimated the impact of PCV-7 vaccination strat-
egies compared to the current practice (no vaccination
schedule) in China to address primary major public
health issue faced by Chinese policy-makers. Because
several studies have shown that the efficacy of two infant
doses plus a booster (2p + 1) was similar to that of 3 in-
fant doses and a booster (3p + 1), we assumed an imple-
mentation of a 2p + 1 schedule, with vaccines given at 4,
6 and 12 months of age [24-26].
Initially, four pneumococcal diseases were included in
the model: meningitis, bacteremia, community-acquired
pneumonia (CAP) and acute otitis media (AOM). These
four diseases can lead to complications, including tympa-
nostomy, neurological hearing impairment, neurological
disability, or death from pneumococcal disease. In the
literature, the model is conceptualized as an extensively re-
ported decision-tree framework that terminates in 11 mu-
tually exclusive outcomes (Figure 1). The cycle lengths of
the model in the time periods 0–4 years and 5–100 years
are 1 month and 1 year, respectively. To simplify the
model, adverse events were omitted from the analysis
because pneumococcal conjugate vaccines are well tol-
erated and lead to only mild adverse events, such as
injection-site reactions.
The analysis was modified to suit China, with costs in
2011 Chinese Yuan (CYN) converted into US dollars.
Health outcomes were presented as the numbers of
cases and deaths. Using the standardized methods rec-
ommended by the WHO, the estimated health out-
comes were translated into gained quality-adjusted life
years (QALYs). The incremental cost per QALY gained
was used as the primary outcome. A yearly discount rate
of 3% was used for both costs and health benefits.
Univariate and probabilistic sensitivity analyses were
performed to explore parameter uncertainty.
Epidemiological and disease data
Model inputs for epidemiology data were obtained from
Chinese studies to the greatest possible extent; however,
the paucity of epidemiological pneumococcal disease stud-

























Figure 1 The structure of the model, illustrating the two alternatives for PCV vaccination (including no vaccine) and possible
subsequent events for each child. The following health states are included: meningitis, bacteremia, pneumonia, AOM and no infection.
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Asian countries are in geographical proximity, and East
Asian people are genetically and culturally related. These
commonalities should theoretically result in similar sero-
types and transmission patterns of S. pneumoniae. By
searching the PubMed and Medline databases (up to
January 26, 2012), we identified applicable articles on IPD
in East Asia.
Age-specific incidence rates for pediatric cases of 4
pneumococcal diseases were derived from the published
literature. The mean incidence rate of pneumococcal men-
ingitis was estimated from a surveillance study of invasive
bacterial diseases in Chinese children aged 1–23 months
[27]. Additionally, a systematic review of IPD in East Asia
was conducted to assess the probable incidence rate of
pneumococcal meningitis in Chinese children >2 years of
age. The surveillance data from Hong Kong, Taiwan,
Singapore and Japan indicated that the mean incidence
of IPD was 12.8–15.6 per 100,000 people per year [28].
We used the mean value of the above range as the as-
sumed incidence rate of IPD in Chinese children aged
2–5 years. Based on an epidemiological study of IPD in
China, the proportional incidence of meningitis in IPD
is approximately 33.3%, and the proportional incidence
of bacteremia is 66.7% [30]. Thus, the incidence rate of
meningitis could be calculated by the following formula:
33.3% × incidence rate of IPD. The case-fatality rate of
meningitis was derived from a systematic review published
by Ying Chen et al. [2]. Two types of complications from
pneumococcal meningitis (neurologic sequelae and deaf-
ness) were included in the model, and the risks ofneurologic sequelae and deafness were 7.0 and 13.0%, re-
spectively [34].
Due to the lack of incidence data on bacteremia in
Chinese children aged 0-5 years, an indirect method was
used to estimate the incidence rate. As the above Chinese
study indicates that the incidence ratio of bacteremia to
meningitis is nearly 2:1, the incidence rate of pneumococ-
cal bacteremia for children aged 1–23 months was calcu-
lated as two times the incidence rate of pneumococcal
meningitis. For children aged 2–5 years, the incidence
rate of pneumococcal bacteremia was calculated as
66.7% of the incidence rate of IPD. The case-fatality rate
of pneumococcal bacteremia was obtained from studies
reported in Korea and Hong Kong [2,33,37].
No epidemiological study that determined the burden
of pneumococcal pneumonia in China has been reported.
A systematic literature review by Ying Chen et al. sug-
gested that there were 12,815 cases of all-cause pneumo-
nia per 100,000 people per year among Chinese children
aged <59 months, including 384.5 cases of pneumococcal
pneumonia with a 3% S. pneumoniae isolation rate for
pneumonia [2]. However, due to the common practice of
administering antibiotics prior to obtaining cultures, and
as a result of poor culture methods, the proportion of
positive blood cultures or CSF specimens is lower than
expected. This scenario has implications for the current
study because precise estimates of the disease burden
would be highly sensitive to the true S. pneumoniae iso-
lation rate. To avoid underestimating the isolation rate,
we used the estimated isolation rate by O’Brien et al.
The impact of the S. pneumoniae isolation rate on the
Table 1 Probabilities and estimates associated with pneumococcal disease and vaccine efficacy in Chinese children
≤ 5 years of age
Variables Base-case estimate* Ranges for sensitivity analysis Source
Annual incidence rates of disease
Pneumococcal meningitis (<2 years) 0.000051 Base ± 25% [27]
IPD (3-5 years) 0.000142 0.000128–0.000156 [28]
All-cause pneumonia 0.12815 Base ± 25% [2]
All-cause AOM (≤2 years) 0.412 0.012–0.64 [29]
All-cause AOM (3-5 years) 0.381 0.012–0.64 [29]
Proportion of meningitis in IPD 0.3333 Base ± 25% [30]
S. pneumoniae isolation rate for pneumonia 0.08 0.02–0.268 [31]
S. pneumoniae isolation rate for AOM 0.392 0.292–0.49 [32]
Disease outcomes
Case fatality rate of meningitis 0.083 Base ± 25% [2]
Case fatality rate of bacteremia 0.046 Base ± 25% [33]
Case fatality rate of pneumonia 0.00526 Base ± 25% [2]
Probability of disability caused by meningitis 0.07 Base ± 25% [34]
Probability of deafness caused by meningitis 0.13 Base ± 25% [34]
Probability of tympanostomy caused by AOM 0.059 Base ± 25% [13,35]
Serotype coverage rates of PCV-7
IPD 0.45 Base ± 25% [27]
Pneumonia 0.763 Base ± 25% [36]
AOM 0.648 Base ± 25% [37]
Efficacy of PCV-7
IPD 0.974 Base ± 25% [14]
Pneumonia 0.9 Base ± 25% [14]
AOM 0.576 Base ± 25% [15]
Relative efficacy of 2 doses 0.86 0.645–1 [38]
Relative efficacy of 3 doses 1 0.95–1 [24]
Birth cohort size in China 16,000,000 - [39]
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lysis [31]. The mortality rate from all-cause pneumonia
was derived from the systematic review published by
Ying Chen et al. [2].
For AOM, the annual age-specific incidence data in
children were derived from a study in a healthcare set-
ting in Taiwan, China, in 2010 [29]. The reported annual
incidence of acute otitis media was substantially differ-
ent, ranging from 1.2% in an Asian population to 64% in
a Finnish population. Because the incidence of acute oti-
tis media is an important factor in the final economic
analysis, we tested the impact of this input using a sensi-
tivity analysis. The age-specific proportion of cases due
to S. pneumoniae was obtained from a Chinese study by
Wen RJ et al., who investigated the distribution of patho-
genic bacteria in 442 isolates from Chinese children of
various ages with AOM [32]. The probability of tympa-
nostomy was based on data from the United States andFinland [13,35]. As no reliable data were reported, the risk
of sequelae caused by AOM was assumed to be zero.
Vaccine efficacy and coverage
Pneumococcal conjugate vaccines were principally devel-
oped to cover the clinical pneumococcal serotypes en-
countered in North America and Western Europe, which
are typically different from those found in China. The
most common serotypes isolated from Chinese children
with pneumococcal infections are 6A, 6B, 14,19F, 19A
and 23F, while the serotypes covered by PCV-7 are 4,
6B, 9V, 14, 18C, 19F, and 23F. The estimated coverage
rate of invasive isolates by PCV-7 was 45%, according to
2005–2006 surveillance data on children aged <5 years
in eight different regions of China [27]. A recent prospect-
ive surveillance study of children aged <5 years in five
different regions in China reported an estimated 76.3%
coverage rate of PCV-7 for pneumonia [36]. Because there
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used. As the efficacy of PCV-7 in Chinese children is un-
known and as there is no evidence that ethnicity affects
the efficacy of PCV-7, the efficacy assumed in the current
analysis was derived from the Northern California Kaiser
Permanente (NCKP) trial and the Finnish Otitis Media
Vaccine (Finnish OM) study [14,15]. The efficacies in the
prevention of IPD, pneumonia and AOM caused by sero-
types, which were covered by PCV-7, are 97.4, 90.0 and
57.6%, respectively [14,15]. As the vaccine coverage in the
Chinese national vaccination program was close to 99%,
we assumed the coverage of PCV-7 to be 99% [40]. The
efficacy of partial vaccination was provided by the current
model. We assumed that the efficacies of one and two
doses alone are 0 and 86%, respectively, of the efficacy of
the full three doses [38].Net indirect effect (herd immunity)
Studies have shown that the use of a pneumococcal conju-
gate vaccine in young children could markedly decrease
the risk of pneumococcal disease in adults by diminishing
nasopharyngeal vaccine serotypes (i.e., herd immunity)
[41,42]. Recent studies have found that herd protection
had a significant effect on the cost-effectiveness of a uni-
versal PCV7-vaccination program [43]. Herd immunity
was included to calculate the effectiveness of vaccination
in protecting unvaccinated children and adults for a
period of 1 year, respectively. The incidence rates of IPD
in individuals aged 0–4, 5–17, 18–49, 50–64 and 65+
years were 16.5, 1.4, 0.9, 4.2 and 12.1 per 100,000 persons,
respectively, as reported in one recent study from a
Chinese Taiwan district [44]. For children aged 4 years
and younger, there was a 69% decrease in the presence of
vaccine serotypes after the introduction of PCV-7 in the
United Kingdom [45]. For four-dose vaccination sched-
ules, reduction in IPD in the age groups 20–34, 35–64
and ≥65 years were 32% (95% CI: 23–41%), 8% (95% CI:
1–20%) and 18% (95% CI: 11–31%), respectively [42].
Because three-dose vaccination schedules are similar in
direct efficacy to four-dose schedules, the net indirect ef-
fect was assumed to be the same for the two schedules.
Herd protection did not affect AOM or CAP because
there was no evidence supporting an indirect effect of vac-
cination on these diseases.Health outcomes
Vaccine efficacy was assessed by the following key param-
eters: specific disease cases, deaths averted and QALY
gained. Health utility values were assigned to each specific
health state in our model in a range from 1 (perfect
health) to 0 (death). Utility values due to acute episodes of
the disease and long-term sequelae are shown in Table 2
and were derived from previously published data [46-49].Resource Use and costs
The cost associated with pneumococcal disease was de-
termined from a Chinese perspective. The medical and
nonmedical cost parameters used in this analysis are
presented in Table 1. For the four initial diseases, the as-
sumed medical costs were directly associated with treat-
ment for pneumococcal disease in Shanghai Children’s
Hospital, Wuxi Children’s Hospital and Shanghai First
People’s Hospital in 2011. These costs were adjusted based
on the opinions of a Chinese pediatric expert panel. Cases
with other severe comorbidities, such as malignant cancer,
immune disorders and congenital cardiac or respiratory
diseases, were excluded from the cost estimates. The med-
ical costs covered the medical resources consumed in the
treatment of pneumococcal disease, such as medications,
medical care, hospitalization and diagnostic tests. The cost
of productivity lost by a parent taking care of a child with
pneumococcal disease was estimated by an expert panel.
The median daily salary in China ($22.6 according to the
Chinese National Bureau of Statistics) was used to esti-
mate the total opportunity cost of pneumococcal disease
by multiplying work-loss by time [50].
The costs of the long-lasting sequelae of meningitis,
including deafness and neurologic impairment, were in-
cluded in this analysis. As described by Butler JR et al.,
the additional resource consumption for deafness is one
hearing aid per a designated number of years for the
remainder of a patient’s life [51]. The median time and
cost to replace a disabled hearing aid is 6 years and
$635, respectively, according to the expert panel. Ranges
of 3–10 years and $300–1200 were used in the sensitiv-
ity analysis. Individuals with neurological deficits com-
monly require special education and lifetime residential
care, which were included as an additional cost. We as-
sumed that, in accordance with Chinese education law,
children with disabilities would receive 9 years of special
education. The annual cost of special education was de-
rived from the Statistical Yearbook of Chinese Education
[52]. To our knowledge, care in China is always the re-
sponsibility of a family member or members. Thus, we
estimated the cost of care based on the lost productivity
of a family member. The average wage in China was
used to calculate the potential annual economic burden
of neurological deficit [50].
The cost of adding PCV-7 to the vaccination program
included both PCV-7 acquisition and non-vaccine costs.
The per-dose retail price of PCV-7 in China is $127;
however, a discount may be possible when drugs and
vaccines are covered by the Chinese healthcare system.
To account for changing price politics in China, a sensitiv-
ity analysis on this input variable was conducted. Non-
vaccine costs included administration, transport, injection
supplies, training, and other expenses. In the current ana-
lysis, we assumed that the non-vaccine costs associated
Table 2 Cost* and utility of pneumococcal disease in Chinese children ≤5 years of age
Variable Base-case estimate Ranges for sensitivity analysis Source
Cost
Bacteremia per episode 2666.67 793.65–6349.21 Estimated
Meningitis per episode 3587.3 476.19–7936.51 Estimated
Pneumonia per episode 607.3 158.73–1587.3 Estimated
AOM per episode 111.11 31.75–317.46 Estimated
Tympanostomy caused by AOM 333.33 Base ± 25% Estimated
Hearing aids per unit 634.92 300–1200 Estimated
Replacement interval (years) 6 3–10 Estimated
Special education for disability per year 2557.84 158.73–3174.6 Estimated
PCV-7 cost per dose 136.51 102.38–170.63 Estimated
Cost of vaccine administration 1.86 0–3.17 Estimated
Salary per day 22.6 6.3–27.64 Estimated
Work-lost days for disease
Bacteremia 8 6–10 Estimated
Meningitis 9 6–12 Estimated
Pneumonia 7 5–9 Estimated
AOM 5 4–8 Estimated
Utility
Bacteremia 0.9921 Base ± 25% [46-49]
Meningitis 0.9768 Base ± 25% [46-49]
Pneumonia 0.9921 Base ± 25% [46-49]
AOM 0.995 Base ± 25% [46-49]
Tympanostomy caused by AOM 0.82 Base ± 25% [46-49]
Long-term disability 0.6 Base ± 25% [46-49]
Long-term deafness 0.8 Base ± 25% [46-49]
Death 0 - [46-49]
*Costs are presented in US dollars (January 2012 exchange rate, US$ = CYN 6.30).
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the H1N1 vaccine ($1.86) [53].
Sensitivity analysis
Univariate and probabilistic sensitivity analyses were per-
formed to examine the uncertainty within the model [54].
In the univariate sensitivity analyses, the parameters were
varied to evaluate the sensitivity of the findings in the
presence of plausible variations in specific data inputs.
The results of the univariate sensitivity analyses are pre-
sented in a Tornado diagram. The ranges of parameters
used in the univariate sensitivity analyses were obtained
from published literature; when reported data were not
available, a range of ±25% of the base-case value was used
(Tables 1 and 2). The range in vaccine price per dose was
assumed to be $102.38 to $170.63. For the probabilistic
sensitivity analyses, parameters were sampled using the
Monte Carlo method to simulate 1,000 replication out-
comes. The beta distribution was used for incidence rates,
risks, probabilities, proportions and utilities, and thegamma distribution was used for costs. Cost-effectiveness
acceptability curves (CEACs) of vaccination versus no vac-
cination were developed to present the probabilities of
cost-effectiveness at different costs of PCV-7.
Results
Base-case analyses
The projected health outcomes and costs for the “no vac-
cination” and PCV-7 strategies in China are presented in
Table 3, with listed differences between the two strategies.
Over a 5-year period, the model predicted that universal
PCV-7 vaccination in the Chinese birth cohort would pre-
vent 4,222 cases of IPD, 4,061,524 cases of AOM and
472,527 cases of pneumonia, preventing an additional
2,682 deaths from pneumococcal disease. PCV-7 vaccin-
ation was estimated to prevent 235,819 cases of tympa-
nostomy from AOM, as well as 97 cases of permanent
disability and 180 cases of deafness from meningitis.
Overall, it was projected that PCV-7 vaccination in a co-
hort of nearly 16,000,000 Chinese infants would lead to
Table 3 Projected health outcomes and costs of pneumococcal conjugate vaccination in a cohort of Chinese infants on
lifetime disease burden compared with no vaccination
Disease type/health outcome No vaccination PCV-7 Vaccination Differences*
Cases for birth cohort
Pneumococcal bacteremia 7,402 4,587 -2,815
Pneumococcal meningitis 3,701 2,293 -1,407
Pneumococcal AOM 12,616,500 8,554,976 -4,061,524
Pneumococcal pneumonia 780,407 307,880 -472,527
Disability caused by pneumococcal meningitis 255 158 -97
Deafness caused by pneumococcal meningitis 474 294 -180
Tube insertion caused by pneumococcal AOM 732,905 497,086 -235,819
Death caused by pneumococcal disease 4,674 1,993 -2,682
Death caused by pneumococcal bacteremia 335 207 -128
Death caused by pneumococcal meningitis 302 188 -114
Death caused by pneumococcal pneumonia 4,037 1,597 -2,439
Efficacy of herd immunity
Pneumococcal bacteremia 28,310 23,562 -4,748
Pneumococcal meningitis 19,088 7,817 -11,270
Disability caused by pneumococcal meningitis 3,627 1,485 -2,141
Deafness caused by pneumococcal meningitis 4,963 2,033 -2,930
Death caused by pneumococcal invasive disease 5,449 3,934 -1,515
Costs for birth cohort ($, discounted)
vaccine cost (including administration) 0 6,438,882,934 6,438,882,934
Meningitis medical cost 13,275,258 8,226,631 -5,048,627
Bacteremia medical cost 19,739,872 12,232,718 -7,507,154
Pneumonia medical cost 473,942,531 186,976,189 -286,966,342
AOM medical cost 1,401,833,288 950,552,900 -451,280,388
Long-term cost of sequelae 6,428,514 3,974,969 -2,453,545
Nonmedical cost 1,581,876,301 1,144,173,592 -437,702,709
Subtotal 3,497,095,763 8,745,019,933 5,247,924,169
Costs in herd immunity 323,840,533 169,576,767 -154,263,765
Total 3,820,936,296 8,914,596,700 5,093,660,404
QALYs loss (without herd immunity) 2,310,183 2,300,288 43,543#
QALYs loss (with herd immunity) 112,072,439 112,019,001 53,438#
ICER without heard immunity ($/QALY gained) 530,354
ICER with heard immunity ($/QALY avoided) 95,319
*PCV-7 vaccination strategy compared with no vaccination.
#The incremental QALYs gained by PCV-7 vaccination strategy.
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the lifetime of the infants. Accounting for herd immun-
ity, 16,018 cases of IPD and 1,515 deaths in the adult
population would be prevented by PCV-7 vaccination,
which translates into an additional 43,543 QALYs (dis-
counted by 3%) gained over the lifetime of the vacci-
nated infants.
The medical and nonmedical cost of pneumococcal
disease was estimated to be $3.5 billion (discounted by3%) in an unvaccinated birth cohort; this value was
driven by the nonmedical cost and the costs associated
with AOM. The inclusion of the costs associated with
IPD in unvaccinated populations increased the total to
almost $3.8 billion (Table 3). A universal PCV-7 vaccin-
ation program would save $1,345 million in costs associ-
ated with pneumococcal disease, including savings in the
Chinese birth cohort ($1,190 million) and herd immun-
ity for unvaccinated populations ($154 million). The cost
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for a birth cohort of nearly 16,000,000 Chinese infants
was estimated to be $6.44 billion.
From a societal perspective, the incremental cost-
effectiveness ratio of universal PCV-7 vaccination over
no vaccination was $530,354 per QALY gained. When
the indirect effect of herd immunity from vaccination
was taken into account, the cost per QALY gained was
$95,319 (Table 3).
Sensitivity analyses
The results of the one-way sensitivity analyses are shown
in a tornado diagram (Figure 2), which presents the 37
most sensitive input variables around the base-case value
in terms of the discounted ICER (≥1% of base-case ICER
and listed in descending order). The projected ICER of
PCV-7 vaccination versus no vaccination was most sensi-
tive to the cost of PCV-7 per dose. The cost varied from
$102.38 to $170.63, and the corresponding ICERs were
$64,711 and $124,957, respectively. The reduction of IPDFigure 2 Tornado diagram presenting a one-way sensitivity analysis f
the bars represents the differences in ICERs with low (left) and high (right)for herd immunity in adults (<5 year) and annual inci-
dence of IPD in children (<5 year) were the second- and
third-most influential factors, respectively. As expected, a
higher S. pneumoniae isolation rate for pneumonia pre-
dicted more favorable ICERs.
In China, the break-even costs of the PCV-7 vaccine
with and without herd immunity were $25.87 and $29.05,
respectively (Figure 3). When herd immunity was taken
into account, the per-vaccine cost ranges for very cost-
effective, cost-effective and not cost-effective vaccination
were $29.05 to $35.39, $35.39 to $47.94 and ≥ $47.94, re-
spectively. When herd immunity was not taken into ac-
count, the relevant per-vaccine cost ranges were $25.87 to
$26.97, $26.97 to $29.36 and ≥ $29.36, respectively.
The results were moderately sensitive to the cost of
AOM per episode, the annual incidence of all-cause AOM
in children, the serotype coverage of PCV-7 for IPD and
the S. pneumoniae isolation rate for AOM. Other moder-
ately sensitive factors include the S. pneumoniae isolation
rate for AOM, serotype coverage of PCV-7 for AOM, costor PCV-7 vaccination compared with no vaccination. The length of
parameter values.
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AOM and pneumonia and reduction of IPD in adults
(≥65 year) with herd immunity. Other input model param-
eters, such as the cost of meningitis and bacteremia per
episode, had little impact on projected ICERs (<1% of
base-case ICERs).
Finally, given the willingness to pay $5,569 (per capita
GDP of China in 2011) or $16,707 (three times the
per-capita GDP of China in 2011) per QALY gained,
cost-effectiveness acceptability curves showed that the
probability that a vaccination plan will be cost-effective
is less than 0.5, only when the cost was decreased 75%
and herd immunity was taken into account (Figure 4).
Discussion
Although the incidence rate in China is lower than in
other developing regions, such as Africa and Southeast
Asia, China accounts for 12% of pneumococcal cases
worldwide because it has the largest population [31].
The introduction of PCV vaccines has increased interest
in preventing pneumococcal disease. Our results show
that the routine compulsory vaccination with PCV-7 of
Chinese infants has the potential to significantly de-
crease the disease burden and mortality associated with
S. pneumoniae by 33.8 and 57.4%, respectively. The sur-
veillance data from the regions where PCV-7 has already
been incorporated into the national immunization program
demonstrate the effectiveness of this vaccine [16,55]. In the
United States, a 75% decrease in the all-cause IPD inci-
dence rate was observed within 3 years of vaccine introduc-
































Figure 3 Projected cost per QALY gained by the PCV-7 vaccination pr
per dose with or without herd immunity.prevented in children ≤5 years of age [55]. The estimated
cost associated with pneumococcal disease was reduced by
34.1% in the birth cohort receiving PCV-7 vaccination.
However, our economic analysis indicated that the PCV-7
vaccination program in China is not cost-effective because
the incremental cost per QALY gained is far greater than
three times the per-capita GDP of China, which is the
standard cutoff cost recommended by the WHO Choosing
Interventions that are Cost Effective (WHO-CHOICE)
project. This result persisted even when a 75% discount
rate was applied to the per-dose price of PCV-7 [56,57].
To the best of our knowledge, this is the first cost-
effectiveness evaluation of the economic outcome of
PCV-7 vaccination implementation in China. The re-
sults may be helpful for Chinese health-policy makers in
deciding whether to add PCV-7 to the compulsory rou-
tine vaccination program in China.
Our results indicated that the cost of the vaccine itself
drives the cost of PCV-7 vaccination, accounting for 72.2
or 73.6% of the total cost with or without herd immunity,
respectively. The one-way sensitivity analysis showed that
varying the cost of PCV-7 from 75 to 125% of the base-
case value yielded the most influential parameters. The
literature has shown that the cost of PCV-7 vaccine acqui-
sition in the rest of the world is substantially different
from the cost in China. For example, the estimated
current cost of PCV-7 per dose in the European national
immunization program was nearly $80, which is 41%
lower than the cost in China; [58] however, only a 75%
reduction in vaccine cost would yield a nearly 75% prob-
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Figure 4 Cost-effectiveness acceptability curves of base-case vaccination schedules and of alternative scenarios regarding PCV-7 price.
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effectiveness, Figure 3 suggests that the cost of PCV-7
should be reduced to at least 35.1 or 21.5% of the base-
case value with or without herd immunity, respectively.
This suggestion is in accordance with the study by Mari
Nakamura et al., which indicated that vaccination with
PCV-7 would be cost-effective at a per-dose cost of $10
for lower-middle-income (2008 GNI per capita: $976–
3,855) and $20 for upper-middle-income (2008 GNI per
capita: $3,856–11,905) countries [59]. The costs of intro-
ducing a compulsory routine pneumococcal vaccination
program in China should be weighed against the losses
based on more information regarding budget impact, af-
fordability and sustainability.
Our findings project a 38% reduction in IPD following
PCV-7 vaccination in China, which is greater than the
reduction in pneumococcal AOM (32%); however, our
results indicate that the major contributor to the cost sav-
ings from the introduction of PCV-7 vaccination emerges
from a reduction in costs related to pneumococcal AOM.
Otitis media has relatively less serious outcomes and a
higher incidence rate compared with IPD according to
this analysis, in agreement with the findings of previous
studies. Pneumococcal non-typeable Haemophilus influ-
enza protein D conjugate vaccine (PHiD-CV) is a newly
licensed 10-valent pneumococcal conjugate vaccine. It
may protect against diseases caused by non-typeable H.
influenzae (NTHi) [60]. Vaccination with PHiD-CV is
projected to lead to a 33.6% decrease in the overall inci-
dence of otitis media and a 35.6% reduction in the inci-
dence of otitis media caused by H. influenzae [60]. It is
expected that a more favorable ICER would be achieved ifthe cost of PHiD-CV were comparable to that of PCV-
7. The base-case analysis also showed that the cost
associated with pneumococcal pneumonia was the sec-
ond major contributor to the total economic burden of
pneumococcal disease. According to a recent study by
Kai-Hu Yao et al., serotype 19A, which is not covered by
PCV-7, is the second most common serotype in Chinese
children [36]. The serotype coverage rate of PCV-13,
which does include 19A, for pneumococcal pneumonia
is 16% higher than that of PCV-7. New pneumococcal
vaccines with higher serotype coverage rates should be
given serious consideration when deciding whether to
support pneumococcal vaccination in China. The current
analysis should be updated when PCV-10, PCV-13 and
PHiD-CV are supplied in China.
Previous studies have shown that the addition of indir-
ect effects offer considerable support for the universal
vaccination of young children [43]. Although efforts to
introduce PCVs in developing countries are increasing,
few published reports have used local data to account
for the role of herd immunity from universal childhood
PCV-7 vaccination in reducing adult cases of IPD. The
evidence from early epidemiological studies showed that
herd immunity decreases the overall burden of pneumo-
coccal disease [41,55]. In comparison to a model that does
not account for herd immunity from universal infant
PCV-7 vaccination in China in terms of reducing adult
cases of IPD, our base-case analysis indicated that the
addition of this indirect effect yielded a substantially lower
ICER (Table 3). The results of the current analysis consist-
ently demonstrated a more favorable economic outcome
when herd immunity was included in the vaccination
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health-economic benefits of PCV-7 would be reduced by
serotype replacement with uncovered virulent strains. Re-
cent epidemiological data from the United States, Europe
and Singapore suggest ongoing and significant serotype
changes in children, with 19A in particular increasing in
incidence [61-63]. The adoption of PCVs with broader
serotype coverage is strongly recommended. Meanwhile,
continued surveillance of IPD is necessary to provide epi-
demiological data on potentially emerging serotypes.
The present analysis took a conservative approach to es-
timating the health benefits of PCV-7 vaccination for three
reasons. First, the increasing frequency and rapid spread
of antibiotic-resistant S. pneumoniae is a global problem,
and serious antibiotic resistance has been observed in
Chinese clinical practice. According to an epidemiological
study by Lin Zhou et al., the rates of resistance to erythro-
mycin and azithromycin in S. pneumoniae in Beijing were
96.4 and 97.1%, respectively. Furthermore, 64.3% of all
pneumococcal isolates were multidrug-resistant S. pneu-
moniae (MDRSP) [64]. To manage pneumococcal disease
caused by antibiotic-resistant S. pneumoniae, superior
antibiotics and longer hospital stays are necessary, leading
to increased consumption of health-associated financial
resources. In the present analysis, resource savings from
the prevention of antibiotic-resistant infection were not
accounted for among the potential savings from PCVs be-
cause local data on the subject are inadequate and difficult
to collect. The exclusion of such infections underestimates
the cost-effectiveness of universal PCV-7 vaccination in
China. Second, the most influential factor captured by our
model was the S. pneumoniae isolation rate for pneumo-
nia. Our findings indicated that a higher isolation rate
would yield more favorable health benefits from vaccin-
ation. The isolation rate used in the base-case analysis
were 8%, which is greater than the estimates provided by
Ying Chen et al.; [2] however, as a result of widespread
antibiotic abuse in China, pathogen cultures from blood
and cerebrospinal fluid (CSF) are rarely positive, and naso-
pharyngeal isolates are the main method of surveillance
for pneumococcal epidemiology in Chinese children. Ac-
cording to a study by Rudan et al., the estimated propor-
tion of pneumococcal pneumonia in all-cause radiological
and fatal pneumonia was 30–50% in Chinese children
aged ≤5 years [65]. One recent study conducted in Beijing
found that nearly 55% of children with severe community-
acquired pneumonia had S. pneumoniae in their lung tis-
sues, as identified by PCR and/or Southern blotting [66].
Because of the limitations of these data, our model did not
adjust for the isolation rate for S. pneumoniae. These
conservative estimates may have led us to underestimate
the impact of a PCV program. Finally, several studies
have indicated that the benefits of PCV7 vaccination
extend beyond the covered serotypes. A separate studyfound a 20% reduction in non-pneumonia acute respira-
tory infections in children aged ≤2 years after the adop-
tion of PCV-7 [67]. Data from South Africa and the
United States indicated that PCV may reduce the inci-
dence of viral-associated pneumonia [68]; however, our
model does not consider these broader benefits of the vac-
cine and thus underestimates the impact of the vaccine.
This study has several weaknesses and limitations.
First, in the absence of an epidemiological survey, no
China-specific data were available for some of the model
inputs, and there was substantial variation in data qual-
ity. Thus, such results must be carefully interpreted be-
cause multiple sensitive variables limit the extrapolation
of results (e.g., the incidence of all-cause AOM, S. pneu-
moniae isolation rate, and efficacy of herd immunity).
Fortunately, our sensitivity analyses indicated that these
variables do not significantly affect the ICERs in terms
of the WHO-CHOICE standards. Second, to simplify the
model structure and to avoid including too many uncer-
tainties, the current model does not include all diseases
associated with S. pneumonia and adverse reactions re-
lated to the vaccination as other economic analyses do,
such as sinusitis, septic arthritis and injection-side reac-
tions [21,22,69-71]. However, because the excluded dis-
eases or events (e.g., seizure disorders and vision loss)
are rare, their impact was too minor to be captured by
the model. Third, almost all China-specific data in this
analysis, such as the serotype coverage of PCV-7 for pneu-
monia, were obtained from hospital-based studies. These
studies were mostly conducted in teaching hospitals in
large cities such as Beijing, Shanghai and Guangzhou,
where sanitary and health conditions are likely better than
those in small cities and rural regions. Thus, such data
may not be representative of the entire Chinese popula-
tion, and there are uncertainties regarding the robustness
of the analysis. If better supported and more representa-
tive epidemiological data become available in the future,
the model outcome will be more accurate, and the relative
effectiveness of the vaccines in preventing IPD will be
greater. Fourth, potential uncertainties and biases result
from the several assumptions and expert opinions used in
this model, such as the efficacy of PCV-7 vaccination on a
three-dose schedule and the productivity loss of parents
who must care for their children. We adjusted these
assumptions in the sensitivity analysis to determine the
robustness of the model. Fifth, as other analyses have
showed that herd immunity had a significant effect on
cost-effectiveness, [43] it should be carefully explained
that the current analysis used the indirect efficacy data
from other countries, where the patterns of mixing and
serotype may differ greatly from that of China. Finally,
changes in health-resource consumption and quality of
life due to vaccine-related adverse events were not in-
cluded in the current analysis, which may lead to an
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cination would have been more unfavorable if such expen-
ditures had been included; however, the available evidence
from large-scale studies indicates that PCV-7 was well tol-
erated and that the impact on cost and quality of life
would be minimal. Despite these shortcomings, our ana-
lysis provides insight into the potential of PCVs to reduce
the burden of pneumococcal disease.Conclusion
The addition of PCV-7 to the Chinese vaccination program
could prevent a considerable number of pneumococcal dis-
eases. The economic results of this analysis indicate that a
vaccination strategy based on QALYs gained is not cost-
effective in comparison with a no-vaccination strategy,
even when accounting for herd immunity. The sensitivity
analyses indicate that the model outcome is sensitive to
some parameters, such as the price of PCV-7 and the in-
cidence of pneumococcal diseases in China. Thus, to
better inform healthcare decision-making, further work
is needed to improve surveillance data in China. Fur-
thermore, due to the high price of the PCV-7 vaccine
and its partial efficacy when applied to the population of
Chinese infants, other vaccination policies should be ex-
plored for improvement of health resource allocation.
Children with high risk of developing pneumococcal
diseases should be emphasized in the economic analysis
if the non-compulsory vaccination is considered.Competing interests
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